Summary
What is known and objective: The prognostic value of ribonucleotide reductase M1 (RRM1) in patients with pancreatic cancer receiving gemcitabine chemotherapy has been evaluated in several studies. However, the conclusions remain controversial.
Methods:
By searching the PubMed and Embase databases, we conducted a metaanalysis to evaluate the prognostic significance of RRM1 expression in patients with pancreatic cancer receiving gemcitabine chemotherapy. Studies were pooled, and the hazard ratio (HR) and its corresponding 95% confidence interval (CI) were calculated.
Results: Nine relevant articles were included for this meta-analysis study. Our results revealed that the high-RRM1 expression patients had significantly poorer overall survival (HR = 1.70, 95% CI = 1.33-2.16, P heterogeneity = .061, I 2 = 44.8%) and disease-free survival (HR = 1.84, 95% CI = 1.56-2.18, P heterogeneity = .669, I 2 = 0%) than the low-RRM1 expression patients. Furthermore, a statistically significant association between RRM1 expression and OS was found among both Japanese (HR = 1.80, 95% CI = 1.36-2.37, P heterogeneity = .843, I 2 = 0%) and American patients (HR = 1.76, 95% CI = 1.60-1.94, P heterogeneity = .439, I 2 = 0%).
What is new and conclusion:
In conclusion, the expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. RRM1 expression assessment could provide more detailed information for patients with pancreatic cancer and could be used to optimize therapeutic schemes.
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gemcitabine, meta-analysis, pancreatic cancer, ribonucleotide reductase M1 survival rate is also only 15%-25% due to the high recurrence rate. 5, 6 Chemotherapy and radiation therapy are important following surgical resection, and gemcitabine, a pyrimidine nucleotide analogue, has become a standard chemotherapeutic agent in this context. 7, 8 However, the clinical response rate to gemcitabine is still limited, largely because of the profound drug resistance inherent in PC. The choice of patients who gain real benefits from gemcitabine may be an important stepping stone towards improving the results of therapy for PC.
Ribonucleotide reductase M1 (RRM1) is a multimeric enzyme converting ribonucleotides to deoxyribonucleosides; both are needed for polymerization and repair of DNA. 9, 10 Previous reports showed RRM1 gene expression was associated with gemcitabine resistance.
Patients with advanced pancreatic cancer who showed high levels of RRM1 expression were shown to have a low survival rate following gemcitabine treatment, whereas patients with non-small-cell lung cancer and with low-level RRM1 expression had significant benefits from gemcitabine/cisplatin neoadjuvant chemotherapy. 11, 12 There are several studies assessing the prognostic role of RRM1 expression in patients with pancreatic cancer treated by adjuvant chemotherapy with gemcitabine, and no consistent outcomes are reported. 11, [13] [14] [15] [16] [17] [18] [19] [20] To provide a comprehensive assessment of the overall survival prognostic role of RRM1 expression in patients with pancreatic cancer receiving gemcitabine chemotherapy, we performed a meta-analysis of published studies.
| METHODS

| Search strategy
We searched for relevant studies up to May 2017 through the PubMed and Embase databases with the following terms and their combinations: "pancreatic cancer/pancreatic carcinoma," "gemcitabine," "ribonucleotide reductase M1" and "prognosis/survival." All scanned abstracts, studies and citations were reviewed. Moreover, references of the retrieved manuscripts were also manually crosssearched for further relevant publications.
| Selection criteria
The inclusion criteria included the following: (i) be on patients with pancreatic cancer; (ii) provide overall survival (OS) data to evaluate the role of RRM1 expression in the prognosis of patients with PC; and (iii) provide hazard ratios (HRs) with 95% confidence intervals (CIs) or enable calculation of these statistics from the data presented. The exclusion criteria included the following: (i) studies which used the same population or overlapping database; and (ii) studies of in vitro cell culture models.
| Data extraction
All the available data were extracted from each study by 2 investigators independently according to the inclusion criteria listed above.
The study characteristics were recorded as follows: first author name, publication year, country where the research was performed, number of patients, histology, detection method, antibody used and its dilution, cut-off value for positivity, DFS and OS data.
| Statistical analysis
Statistical analyses were carried out in STATA software, version 12.0 (STATA Corp., College Station, TX, USA), and all tests were 2-sided. We calculated the hazard ratios (HRs) and 95% confidence intervals for survival data. The heterogeneity of the studies was assessed using the Cochran's Q test (considered significant for P < . 10) and was quantified by the I 2 statistic. Both fixed-effects (MantelHaenszel) and random-effects (Der Simonian and Laird) models were used to combine the data. Publication bias was evaluated by visual inspection of symmetry of Begg's funnel plot and assessment of Egger's test (P < .05 was regarded as representative of statistical significance).
| RESULTS
| Characteristics of the studies
A total of 395 papers were indentified from the databases as we described above. After deleting the duplications, 288 papers were left; 239 articles were discarded because of irrelevance. One other potential eligible paper was obtained by screening the references of reviews. Of the remaining 49 papers, 9 articles were excluded for being animal studies; 14 papers were letters, reviews or meta-analysis, and 26 articles qualified for full-text reading. After full-text reading, 17
articles were deemed unsuitable and were therefore excluded, and 9
articles were identified to be included for qualitative analysis. Finally, 9 studies composed of 766 patients with PC were incorporated into the current meta-analysis. The flow chart of selection of studies and reasons for exclusion is presented in Figure 1 . The main characteristics of the eligible studies are shown in Table 1 .
| Quantitative synthesis
All 9 studies including 766 patients explored the prognostic significance of RRM1 expression in patients with pancreatic cancer receiving gemcitabine chemotherapy. We performed pooled analysis with available data on the correlation between RRM1 expression and overall survival (OS). The pooled results showed that the high-RRM1 expression patients had significantly poorer outcomes than the low-RRM1 expression patients (HR = 1.70, 95% CI = 1.33-2.16, P heterogeneity = .061, I 2 = 44.8%) (Figure 2A ). In the subgroup analysis stratified by country, a statistically significant association was found among both Japanese (HR = 1.80, 95% CI = 1.36-2.37, P heterogeneity = .843, I 2 = 0%) and
American patients (HR = 1.76, 95% CI = 1.60-1.94, P heterogeneity = .439, I 2 = 0%) ( Figure 2B ). In subgroup analysis based on detection method, a statistically significant association was found in the qRT-PCR group (HR = 1.75, 95% CI = 1.58-1.93, P heterogeneity = .889, I 2 = 0%) and in the IHC group (HR = 1.67, 95% CI = 1.08-2.57, P heterogeneity = .010, I 2 = 67.1%) ( Figure 2C ). Moreover, we performed pooled analysis with available data on the correlation between RRM1 expression and disease-free survival (DFS). The pooled results showed that the high-RRM1 expression patients had significantly poorer DFS than the low-RRM1 expression patients (HR = 1.84, 95% CI = 1.56-2.18, P heterogeneity = .669, I 2 = 0%) (Figure 3 ). 
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| Sensitivity analysis
Sensitivity analyses were performed to assess the influence of individual data set on the pooled HRs by sequential removing each eligible study. Any single study was omitted, whereas the overall statistical significance did not change, indicating that our results were statistically robust (Figure 4 ).
| Publication bias
Finally, the Egger's regression test showed no evidence of asymmetrical distribution in the funnel plot in RRM1 expression in patients with pancreatic cancer receiving gemcitabine chemotherapy (Begg's test P = .592; Egger's test P = .993) ( Figure 5 ).
| DISCUSSION
Pancreatic cancer is one of the most highly malignant diseases. Due to its low cure rate, the mortality rate is almost as high as the incidence. 21, 22 Resection is linked to improved survival, but is only possible in about 10%-20% of patients. 23 Postoperative adjuvant therapy may improve long-term survival. 24 Adjuvant chemotherapy with gemcitabine is now considered standard of care after radical resection for PC. Ribonucleotide reductase (RRM) is the speed-limiting enzyme in DNA synthesis. It is divided into 2 subgroups: RRM1 and RRM2.
25,26
The M1 subgroup is the binding site of RR, and the organic radical of the group of M2 is responsible for the activity of the enzyme. 27, 28 Although the relationship between RRM1 level and response to gemcitabine has been identified, it has been shown that RRM2 is not expressed and the enzyme activity remains the same. 29 The results of our meta-analysis showed significant correlations of RRM1 expression with overall survival (HR = 1.70, 95% CI = 1.33-2.16, P heterogeneity = .061, I 2 = 44.8%) and disease-free survival (HR = 1.84, 95% CI = 1.56-2.18, P heterogeneity = .669, I 2 = 0%) in patients with pancreatic cancer receiving gemcitabine chemotherapy, implying that RRM1 expression may be an important factor for gemcitabine resistance. An explanation of RRM1 expression associated with gemcitabine resistance is the fact that RRM1 is the large subunit of ribonucleotide reductase, which is needed for DNA synthesis.
10,30
The dCTP analogue gemcitabine inhibits DNA strand synthesis, 
| WHAT IS NEW AND CONCLUSION
Despite the limitations of this meta-analysis, our study confirmed that the expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. RRM1 expression assessment could provide more detailed information for patients with pancreatic cancer and could be used to optimize therapeutic schemes. Further studies with larger data sets and well-designed models are required to validate our findings. port and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. 
